Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 650 JPY 0.67% Market Closed
Market Cap: 1.3T JPY
Have any thoughts about
Eisai Co Ltd?
Write Note

Net Margin
Eisai Co Ltd

4.5%
Current
6%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.5%
=
Net Income
32.6B
/
Revenue
733.8B

Net Margin Across Competitors

Country JP
Market Cap 1.3T JPY
Net Margin
4%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 710.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.5B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 202.7B CHF
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Net Margin
13%
Country IE
Market Cap 146B USD
Net Margin
-126%
No Stocks Found

Eisai Co Ltd
Glance View

Market Cap
1.3T JPY
Industry
Pharmaceuticals

Eisai Co., Ltd., founded in 1941 and headquartered in Tokyo, Japan, stands as a prominent global player in the pharmaceutical industry, dedicated to research and development in areas such as neurology and oncology. With a mission encapsulated in their philosophy of "human health care" (hhc), Eisai strives not only for profit but also for the well-being of patients, positioning itself as a company that deeply values purpose alongside its financial goals. Over the years, Eisai has gained recognition for its innovative products, particularly the Alzheimer's treatment, Aricept, which has generated a substantial portion of its revenue. Investors might find this focus on neurodegenerative diseases particularly compelling, given the aging global population and the increasing prevalence of conditions like Alzheimer's. Eisai's commitment to innovation is complemented by strategic partnerships and collaborations, including notable alliances with big biotech and pharmaceutical companies, enhancing its research capabilities and market reach. With a firm commitment to sustainability and environmental issues, the company not only focuses on profitability but also adheres to a long-term vision that resonates with contemporary investment ideals. As Eisai moves forward, its pipeline of products, including promising cancer therapies, offers investors a glimpse into its growth potential and the company's adaptability within a rapidly changing healthcare landscape. This combination of ethical responsibility, strategic growth, and market relevance positions Eisai as an intriguing prospect for investors searching for both stability and potential in the pharmaceutical sector.

Intrinsic Value
7 322.83 JPY
Undervaluation 36%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.5%
=
Net Income
32.6B
/
Revenue
733.8B
What is the Net Margin of Eisai Co Ltd?

Based on Eisai Co Ltd's most recent financial statements, the company has Net Margin of 4.5%.